The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Int J Psychiatry Clin Pract. 2023 Jun;27(2):145-150. doi: 10.1080/13651501.2022.2138444. Epub 2022 Oct 29.
Accumulating evidence suggests that the effects of ketamine administered intravenously at subanaesthetic doses on both anhedonic symptoms and suicidal ideation occur independently of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). This study sought to determine the relationship between anhedonia and suicidal ideation after serial ketamine infusions.
A total of 79 subjects with either treatment-refractory MDD ( = 60) or BD ( = 19) were included in a clinical ketamine study. The Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor and the first five items of the Scale for Suicidal Ideations (SSI-Part I) were used to assess anhedonia symptoms and suicidal ideation, respectively.
At baseline, anhedonia, as measured by the MADRS, was not significantly associated with suicidal ideation or specific suicide-related ideation as measured by SSI-Part I (all 's > 0.05). Only the 'wish to die' and 'desire to make a suicide attempt' items were positively associated with anhedonia at two weeks after the sixth ketamine infusion, which was independent of the reductions in depressive symptoms (all 's < 0.05).
Anhedonia as measured by the MADRS appeared to not be positively related to suicidal ideation after serial ketamine infusions.KEY POINTSSerial ketamine (0.5 mg/kg) infusions have shown quick and dramatic antisuicidal and antianhedonic effects in patients with depression.The association between anhedonia and suicidal ideation after serial ketamine infusions is unclear.Anhedonia appeared to not be positively related to suicidal ideation after serial ketamine infusions.
越来越多的证据表明,静脉给予亚麻醉剂量氯胺酮对快感缺失症状和自杀意念的影响,与重性抑郁障碍(MDD)和双相障碍(BD)中的抑郁症状无关。本研究旨在确定连续氯胺酮输注后快感缺失与自杀意念之间的关系。
共有 79 名治疗抵抗性 MDD( = 60)或 BD( = 19)患者纳入了一项临床氯胺酮研究。采用蒙哥马利-阿斯伯格抑郁评定量表(MADRS)快感缺失因子和自杀意念量表(SSI-Part I)的前五个条目分别评估快感缺失症状和自杀意念。
在基线时,MADRS 评估的快感缺失与自杀意念或 SSI-Part I 评估的特定自杀相关意念无显著相关性(所有's > 0.05)。只有“想死”和“有自杀企图的愿望”两个条目与第六次氯胺酮输注后两周的快感缺失呈正相关,且与抑郁症状的减轻无关(所有's < 0.05)。
MADRS 评估的快感缺失似乎与连续氯胺酮输注后自杀意念无正相关。
连续氯胺酮(0.5mg/kg)输注在抑郁症患者中显示出快速而显著的抗自杀和抗快感缺失作用。连续氯胺酮输注后快感缺失与自杀意念之间的关系尚不清楚。连续氯胺酮输注后,快感缺失似乎与自杀意念无正相关。